CARBOPROST TROMETHAMINE INJECTION USP SOLUTION

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

CARBOPROST (CARBOPROST TROMETHAMINE)

Disponible depuis:

JUNO PHARMACEUTICALS CORP.

Code ATC:

G02AD04

DCI (Dénomination commune internationale):

CARBOPROST

Dosage:

250MCG

forme pharmaceutique:

SOLUTION

Composition:

CARBOPROST (CARBOPROST TROMETHAMINE) 250MCG

Mode d'administration:

INTRAMUSCULAR

Unités en paquet:

15G/50G

Type d'ordonnance:

Prescription

Descriptif du produit:

Active ingredient group (AIG) number: 0133100001; AHFS:

Statut de autorisation:

APPROVED

Date de l'autorisation:

2023-05-26

Résumé des caractéristiques du produit

HOW TO STORE IT
PRODUCT MONOGRAPH
PR
CARBOPROST TROMETHAMINE INJECTION USP
250 mcg/mL carboprost (as carboprost tromethamine)
PROSTAGLANDIN
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, ON L5N 2X7
Date of Initial Authorization:
May 8, 2023
Date of Revision:
May 25, 2023
CONTROL NO. 265917
_` _
_ _
_Page 2 of 23 _
HOW TO STORE IT
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................ 3
SUMMARY OF PRODUCT INFORMATION
.................................................... 3
INDICATIONS AND CLINICAL USE
................................................................ 3
CONTRAINDICATIONS
......................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................... 4
ADVERSE REACTIONS
......................................................................................
7
DRUG INTERACTIONS
......................................................................................
9
DOSAGE AND ADMINISTRATION
.................................................................. 9
OVERDOSAGE
...................................................................................................
10
ACTION AND CLINICAL PHARMACOLOGY
............................................... 11
STORAGE AND STABILITY
............................................................................
11
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................... 12
PART II: SCIENTIFIC INFORMATION
.................................................................. 13
PHARMACEUTICAL INFORMATION
............................................................ 13
DETAILED PHARMACOLOGY
.......................................................................
14
TOXICOLOGY
....................................................................................................
16
REFERENCES
.....................................................................................................
19
PART